

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-71 (canceled).

Claim 72 (new): A method for enhancing an immune response in a patient, comprising administering to the patient a composition comprising an isolated polypeptide, wherein the polypeptide comprises SEQ ID NO: 8, and wherein said composition enhances an immune response in the patient.

Claim 73 (new): The method of claim 72, wherein the composition further comprises at least one component selected from the group consisting of: physiologically acceptable carriers; and non-specific immune response enhancers.

Claim 74 (new): The method of claim 73, wherein the physiologically acceptable carrier is selected from the group consisting of: water, saline, alcohol, lipids, waxes, buffers, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, magnesium carbonate and biodegradable microspheres.

Claim 75 (new): The method of claim 73, wherein the non-specific immune response enhancer is an adjuvant.

Claim 76 (new): The method of claim 72, wherein the composition is administered by injection.

Claim 77 (new): A method for enhancing an immune response in a patient, comprising administering to the patient a composition comprising an isolated polypeptide, wherein the polypeptide comprises a sequence selected from the group consisting of sequences having at least 95% identity to SEQ ID NO: 8 and has the same functional properties as SEQ ID NO: 8, and wherein said composition enhances an immune response in the patient.

Claim 78 (new): The method of claim 77, wherein the composition further comprises at least one component selected from the group consisting of: physiologically acceptable carriers; and non-specific immune response enhancers.

Claim 79 (new): The method of claim 78, wherein the physiologically acceptable carrier is selected from the group consisting of: water, saline, alcohol, lipids, waxes, buffers, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, magnesium carbonate and biodegradable microspheres.

Claim 80 (new): The method of claim 78, wherein the non-specific immune response enhancer is an adjuvant.

Claim 81 (new): The method of claim 77, wherein the composition is administered by injection.

Claim 82 (new): A method for enhancing an immune response in a patient, comprising administering to the patient a composition comprising a fusion protein, wherein the fusion protein comprises SEQ ID NO: 8, and wherein said composition enhances an immune response in the patient.

Claim 83 (new): The method of claim 82, wherein the composition further comprises at least one component selected from the group consisting of: physiologically acceptable carriers; and non-specific immune response enhancers.

Claim 84 (new): The method of claim 83, wherein the physiologically acceptable carrier is selected from the group consisting of: water, saline, alcohol, lipids, waxes, buffers, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, magnesium carbonate and biodegradable microspheres.

Claim 85 (new): The method of claim 83, wherein the non-specific immune response enhancer is an adjuvant.

Claim 86 (new): The method of claim 82, wherein the composition is administered by injection.

Claim 87 (new): A method for enhancing an immune response in a patient, comprising administering to the patient a composition comprising a fusion protein, wherein the fusion protein comprises a sequence selected from the group consisting of sequences having at least 95% identity to SEQ ID NO: 8 wherein the sequence has the same functional properties as SEQ ID NO: 8, and wherein said composition enhances an immune response in the patient.

Claim 88 (new): The method of claim 87, wherein the composition further comprises at least one component selected from the group consisting of: physiologically acceptable carriers; and non-specific immune response enhancers.

Claim 89 (new): The method of claim 88, wherein the physiologically acceptable carrier is selected from the group consisting of: water, saline, alcohol, lipids, waxes, buffers, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, magnesium carbonate and biodegradable microspheres.

Claim 90 (new): The method of claim 88, wherein the non-specific immune response enhancer is an adjuvant.

Claim 91 (new): The method of claim 87, wherein the composition is administered by injection.